カテゴリ： GlobalData, アメリカ, 企業調査

Madrigal Pharmaceuticals Inc (MDGL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Madrigal Pharmaceuticals Inc (MDGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10147
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：68
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-3196 (orally administered), is a proprietary, liver-directed, selective thyroid hormone receptor beta, (THR-ß), agonist that can potentially be used for treating several disease with high unmet medical need. The company is developing MGL-3196 for non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-ß agonist), a preclinical compound that has similar thyroid receptor selectivity to MGL-3196. Madrigal is also headquartered in West Conshohocken, Pennsylvania, the US.

Madrigal Pharmaceuticals Inc (MDGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Merger 13
Madrigal Pharma and Synta Pharma Merges 13
Licensing Agreements 15
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Equity Offering 17
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Asset Transactions 35
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Acquisition 36
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc – Key Competitors 37
Madrigal Pharmaceuticals Inc – Key Employees 38
Madrigal Pharmaceuticals Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 06, 2018: Madrigal Pharmaceuticals reports 2018 third quarter 40
Aug 07, 2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements 42
May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements 45
Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 47
Nov 09, 2017: Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results 49
Aug 10, 2017: Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results 51
May 11, 2017: Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results 53
Apr 03, 2017: Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 54
Clinical Trials 56
May 31, 2018: Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial 56
Feb 08, 2018: Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia 58
Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018 59
Dec 06, 2017: Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial 60
Oct 23, 2017: Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead ß-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting 62
Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 63
Aug 01, 2017: Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH 64
May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196 65
Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Madrigal Pharma and Synta Pharma Merges 13
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc, Key Competitors 37
Madrigal Pharmaceuticals Inc, Key Employees 38
Madrigal Pharmaceuticals Inc, Subsidiaries 39

List of Figures
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Madrigal Pharmaceuticals Inc (MDGL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bashas’ Inc.：企業の戦略・SWOT・財務情報
    Bashas' Inc. - Strategy, SWOT and Corporate Finance Report Summary Bashas' Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • AB Science SA (AB)：企業の財務・戦略的SWOT分析
    Summary AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, …
  • Repsol, S.A.：企業の戦略・SWOT・財務分析
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Nanosphere Inc-製薬・医療分野：企業M&A・提携分析
    Summary Nanosphere Inc (Nanosphere) a subsidiary of Cepheid is a medical device company that develops molecular diagnostic tests for disease detection and patient treatment. The company’s products comprise verigene system, instrumentation, bloodstream infection tests, gastrointestinal infection test …
  • Jcb Co., Ltd.：企業の戦略・SWOT・財務分析
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • CTI BioPharma Corp (CTIC)-製薬・医療分野：企業M&A・提携分析
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • Recordati Rare Diseases Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Recordati Rare Diseases Inc (RRD), a subsidiary of Recordati SpA is a biopharmaceutical company that discovers and develops orphan drugs and biologics. The company’s products comprise chemet, neoprofen, panhematin, desoxyn, mustargen, carbaglu, cosmegen, peganone and tranxene, among others. …
  • Union Bank of India：企業のM&A・事業提携・投資動向
    Union Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Union Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Mirvac Group：企業の戦略・SWOT・財務情報
    Mirvac Group - Strategy, SWOT and Corporate Finance Report Summary Mirvac Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Selecta Biosciences Inc (SELB)-製薬・医療分野：企業M&A・提携分析
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a clinical-stage biopharmaceutical company which develops immunotherapies and vaccines to prevent and treat disease. The company’s pipeline products include SEL-212, SELA-070, SEL-701, LMB-100 and others. Its synthetic vaccine particle (SVP) t …
  • Cara Therapeutics Inc (CARA)-医療機器分野：企業M&A・提携分析
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a clinical-stage biotechnology company that develops novel therapeutics for pain and inflammation and pruritus. The company products include kappa receptor agonists and cannabinoid receptors. It offers products for therapeutic areas which include …
  • El Gezirah Hotels & Tourism Co. S.A.E.：企業の戦略・SWOT・財務分析
    El Gezirah Hotels & Tourism Co. S.A.E. - Strategy, SWOT and Corporate Finance Report Summary El Gezirah Hotels & Tourism Co. S.A.E. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • BRF SA：企業のM&A・事業提携・投資動向
    BRF SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BRF SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Arris International Plc：企業の戦略・SWOT・財務情報
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Endonovo Therapeutics Inc (ENDV)：企業の製品パイプライン分析2018
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • Top Glove Corporation Berhad (TOPGLOV)：医療機器：M&Aディール及び事業提携情報
    Summary Top Glove Corporation Berhad (Top Glove) is a manufacturer and distributor of rubber gloves. The company’s products include nitrile gloves, vinyl gloves, latex gloves, surgical gloves, clean room gloves, household gloves, polyisoprene gloves, and cast polyethylene gloves. It also provides th …
  • Exactech Inc (EXAC)：企業の財務・戦略的SWOT分析
    Summary Exactech Inc (Exactech) is a medical device company that offers orthopedic implant devices and related surgical instruments. The company’s products comprise hip implants, shoulder implants, knee implants, extremity implants, biologics and spine, and other products. It also provides biologic …
  • Commercial Bank International PSC：企業の戦略・SWOT・財務情報
    Commercial Bank International PSC - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank International PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • A.P. Moller – Maersk AS (MAERSK B)-石油・ガス分野：企業M&A・提携分析
    Summary A.P. Moller - Maersk A/S (APM) is a business conglomerate that carries out operations in global trade, shipping and energy. It operates through a network of tankers, supply ships, container vessels, car carriers, drilling rigs and special vessels. The company also carries out container termi …
  • Shanghai Jin Jiang International Hotels (Group) Co Ltd：企業の戦略・SWOT・財務情報
    Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆